| Literature DB >> 33156869 |
Yoshimi Ohshima1, Tomomi Higashide1, Kimikazu Sakaguchi1, Makoto Sasaki1, Sachiko Udagawa1, Shinji Ohkubo1,2, Takashi Yoneda3, Kazuhisa Sugiyama1.
Abstract
PURPOSE: To elucidate glaucoma-related fundus abnormalities in patients with primary aldosteronism (PA).Entities:
Mesh:
Year: 2020 PMID: 33156869 PMCID: PMC7647098 DOI: 10.1371/journal.pone.0242090
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of demographics between the PA and control groups.
| Factors | PA, n = 137 | Control, n = 177 | P value |
|---|---|---|---|
| Age (years) | 55.3 ± 10.7 | 56.1 ± 10.1 | 0.742 |
| Male (%) | 73 (53.3) | 89 (50.3) | 0.598 |
| Hypertension (%) | 135 (98.5) | 31 (17.7) | <0.001 |
| Diabetes mellitus (%) | 26 (19.0) | 15 (8.9) | 0.01 |
| Heart disease (%) | 9 (6.6) | 13 (7.6) | 0.716 |
| Glaucoma (%) | 5 (3.7) | 6 (3.4) | 0.901 |
| Glaucoma suspects (%) | 4 (2.9) | 4 (2.3) | 0.713 |
PA = primary aldosteronism.
Chi-squared test or Mann-Whitney U test.
Comparison of glaucoma-related fundus abnormalities between the PA and control groups (per eye).
| PA, n = 272 | Control, n = 352 | OR (95% CI) | P value | |
|---|---|---|---|---|
| 12 (4.4) | 14 (4.0) | 1.11 (0.42–2.94) | 0.83 | |
| Glaucoma | 7 (2.6) | 7 (2.0) | 1.30 (0.37–4.61) | 0.68 |
| Glaucoma suspects | 5 (1.8) | 7 (2.0) | 0.92 (0.29–2.91) | 0.89 |
| 55 (20.2) | 26 (7.4) | 3.18 (1.81–5.57) | <0.001 | |
| Disc (%) | 35 (12.9) | 25 (7.1) | 1.93 (1.05–3.55) | 0.034 |
| Vessel (%) | 26 (9.6) | 4 (1.1) | 9.20 (3.10–27.2) | <0.001 |
| 12 (4.4) | 12 (3.4) | 1.30 (0.48–3.54) | 0.60 | |
| Disc (%) | 12 (4.4) | 12 (3.4) | 1.30 (0.48–3.54) | 0.60 |
| Vessel (%) | 4 (1.5) | 1 (0.3) | 5.24 (0.52–6.16) | 0.16 |
PA = primary aldosteronism; OR = odds ratio; CI = confidence interval; RNFLD = retinal nerve fiber layer defect; Disc = RNFLDs with their central ends at the disc margin; Vessel = RNFLDs with their central ends adjacent to the retinal vessels.
*Optic disc abnormalities meeting the criteria of glaucoma or glaucoma suspects.
Logistic regression model using clustered robust standard error.
Fig 1RNFLDs with their central ends around the retinal vessels.
Representative fundus photos of non-glaucomatous RNFLDs with their central ends around the retinal vessels. Yellow dotted lines indicate the RNFLDs. This case is from the PA group and shows two RNFLDs with their central ends adjacent to the superior retinal vein and artery. (A) Color photo, (B) Red-free image.
Fig 2Cotton-wool spot found in the right eye of a PA patient.
Fundus photos of the right eye of a 35-year-old man with PA. There were two narrow RNFLDs in the macular region (asterisks). A small cotton-wool spot was observed in the middle of the lower RNFLD (arrow). RNFLDs were judged to be almost touching the margin of the non-glaucomatous optic disc. (A) Color photo, (B) Red-free image.
Comparison of RNFLDs between the PA and control groups in subjects without optic disc abnormalities that met the criteria of glaucoma or glaucoma suspects (per eye).
| PA, n = 255 | Control, n = 332 | OR (95%CI) | P value | |
|---|---|---|---|---|
| 42 (16.4) | 13 (3.39) | 4.84 (2.41–9.71) | <0.001 | |
| Disc (%) | 23 (9.0) | 12 (3.6) | 2.64 (1.21–5.73) | 0.014 |
| Vessel (%) | 21 (8.2) | 2 (0.6) | 14.8 (3.39–64.6) | <0.001 |
PA = primary aldosteronism; OR = odds ratio; CI = confidence interval; RNFLD = retinal nerve fiber layer defect; Disc = RNFLDs with their central ends at the disc margin; Vessel = RNFLDs with their central ends adjacent to the retinal vessels.
Logistic regression model using clustered robust standard error.
Factors associated with the presence of RNFLDs with their central ends at the disc margin (per hemiretina, multivariate analysis).
| PA | Control | All | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| PA | NA | NA | 3.52 (1.56–7.92) | 0.002 | ||
| Male | 0.66 (0.16–2.69) | 0.56 | 0.37 (0.13–1.10) | 0.07 | 0.52 (0.24–1.15) | 0.11 |
| Age | 1.03 (0.95–1.10) | 0.49 | 0.98 (0.93–1.04) | 0.56 | 1.00 (0.96–1.04) | 0.94 |
| HT | NA | 0.42 (0.06–2.82) | 0.38 | NA | ||
| DM | 1.82 (0.32–10.3) | 0.50 | 2.92 (0.63–13.5) | 0.17 | 1.90 (0.71–5.12) | 0.20 |
| Superior hemiretina | 3.71 (1.36–10.1) | 0.011 | 1.12 (0.44–2.88) | 0.81 | 1.94 (1.04–3.60) | 0.037 |
| Glaucoma or GS | 750.9 (30.6–18399) | <0.001 | 41.0 (14.4–116.7) | <0.001 | 112.5 (26.8–472.3) | <0.001 |
PA = primary aldosteronism; OR = odds ratio; CI = confidence interval; NA = not applicable; HT = hypertension; DM = diabetes mellitus; GS = glaucoma suspects.
Factors associated with the presence of RNFLDs with their central ends adjacent to the retinal vessels in all subjects (per hemiretina, multivariate analysis).
| Factors | OR (95% CI) | P value |
|---|---|---|
| PA | 19.9 (4.06–97.8) | <0.001 |
| Male | 1.51 (0.50–4.56) | 0.47 |
| Age | 0.97 (0.92–1.02) | 0.25 |
| DM | 1.07 (0.24–4.67) | 0.93 |
| Superior hemiretina | 1.28 (0.57–2.87) | 0.54 |
| Glaucoma or GS | 9.26 (1.46–58.6) | 0.018 |
PA = primary aldosteronism; OR = odds ratio; CI = confidence interval; DM = diabetes mellitus; GS = glaucoma suspects.
Comparison of factors between non-glaucomatous PA patients with and without RNFLDs.
| Factor | PA without RNFLD | PA with RNFLD | P value |
|---|---|---|---|
| n = 94 | n = 34 | ||
| Male (%) | 51 (54.3) | 17 (50.0) | 0.670 |
| Age (years) | 54.9 ±10.7 | 55.2 ± 11.4 | 0.867 |
| Hypertension (%) | 92 (97.9) | 34 (100) | 0.391 |
| Diabetes mellitus (%) | 17 (18.1) | 6 (17.7) | 0.955 |
| Heart disease (%) | 8 (8.51) | 1 (2.94) | 0.276 |
| Dyslipidemia (%) | 30 (31.9) | 12 (35.3) | 0.719 |
| Cerebrovascular disease (%) | 4 (4.3) | 4 (11.8) | 0.121 |
| SAS (%) | 5 (5.32) | 2 (5.88) | 0.901 |
| Pretreatment SBP (mmHg) | 158 ± 19.8 | 154 ± 14.8 | 0.618 |
| Pretreatment DBP (mmHg) | 99.7 ± 12.1 | 94.6 ± 8.39 | 0.253 |
| BMI (kg/m2) | 25.2 ± 4.5 | 24.5 ± 3.7 | 0.850 |
| SBP (mmHg) | 137 ± 17.8 | 137 ± 20.2 | 0.740 |
| DBP (mmHg) | 84.1 ± 12.3 | 86.5 ± 13.1 | 0.419 |
| PAC (ng/dL) | 142.5 ± 69.6 | 193.9 ± 197 | 0.352 |
| PRA (ng/mL/h) | 0.4 ± 0.2 | 0.32 ± 0.19 | 0.421 |
| ARR | 543.7 ± 473.1 | 1015 ± 2022 | 0.085 |
RNFLD = retinal nerve fiber layer defect; SAS = sleep apnea syndrome; SBP = systolic blood pressure; DBP = diastolic blood pressure; BMI = body mass index; PAC = plasma aldosterone concentration; PRA = plasma renin activity; ARR = aldosterone to renin ratio.
*1 n = 41,
*2 n = 11.
Chi-squared test or Mann-Whitney U test.